Effects of Bifidobacterium Longum Subsp. Infantis i18 on Gut Microbiota Development and Health in Early Life (Bifido i18)
Effects of Bifidobacterium Longum Subsp. Infantis i18 Intervention on Early-Life Gut Microbiota Development and Health Outcomes: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Clinical Study
This study aims to evaluate the effects of Bifidobacterium longum subsp. infantis i18 supplementation on symptoms, gut microbiota development, and overall health outcomes in healthy infants and young children in China.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Jie Yuan
- 電話番号:+86 19821872781
- メール:19821872781@163.com
研究場所
-
-
Hebei
-
Zhangjiakou、Hebei、中国
- First Hospital Hebei North University
-
コンタクト:
- Erwei Yuan
- 電話番号:+86 13301878331
- メール:13301878331@163.com
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
For the Probiotic and Placebo Groups:
- Healthy infants and young children aged 0-36 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, receiving formula feeding and/or mixed feeding.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
For the Observational Reference Group:
- Healthy infants aged 0-6 months at enrollment, born at 37-42 weeks of gestation with a birth weight of 2500-4000 g, exclusively breastfed.
- Classified as being at high risk according to the study-defined assessment criteria.
- No clinically diagnosed allergic disease at enrollment.
- Written informed consent provided by the legal guardian.
Exclusion Criteria:
- Maternal history of metabolic or infectious diseases.
- High-risk pregnancy, or maternal history of alcohol, drug, or other substance abuse during pregnancy.
- Antibiotic use within 4 weeks before enrollment.
- Probiotic product use within 4 weeks before enrollment; for infants younger than 1 month, any use since birth.
- Immunosuppressive therapy before enrollment.
- Acute or chronic disease within 4 weeks before enrollment that may significantly affect growth and development.
- Congenital malformations or birth defects.
- Malnutrition requiring hospitalization.
- Known allergy to any component of the study probiotic product.
- Participation in another clinical trial or use of any investigational drug within 3 months before screening; for infants younger than 3 months, any such participation or use since birth.
- Any other condition considered by the investigator to potentially affect participant safety or interpretation of study data.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ群
|
Matching placebo without the probiotic intervention |
|
実験的:プロバイオティクスグループ
|
Bifidobacterium longum subsp. infantis i18 supplementation. |
|
介入なし:Observational Reference Group
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of participants with newly reported allergic symptoms (atopic dermatitis/eczema etc.) as assessed with the structured allergy symptom questionnaire
時間枠:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
二次結果の測定
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
Number of participants with newly reported respiratory symptoms (respiratory tract infection etc.) as assessed with the structured respiratory symptom questionnaire
時間枠:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Number of participants with newly reported gastrointestinal symptoms (constipation etc.) as assessed with the structured gastrointestinal symptom questionnaire
時間枠:From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
From randomisation (Day 0) to the end of follow-up (Day 180; up to 26 weeks), assessed at each scheduled study visit.
|
|
Feeding pattern as assessed with the structured feeding questionnaire
時間枠:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Growth and nutritional status: body weight (kg), length/height (cm) and head circumference (cm) measured with a calibrated scale, infantometer/stadiometer and measuring tape, with age- and sex-adjusted Z-scores per WHO Child Growth Standards
時間枠:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), measured at each scheduled study visit.
|
|
Gut microbiota composition and diversity: relative abundance (%), alpha diversity and beta diversity in faecal samples assessed by metagenomic sequencing.
時間枠:From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
From baseline (Day 0) to the end of follow-up (Day 180; up to 26 weeks), faecal samples collected at each scheduled study visit.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- DICT-2026-01-03
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。